[引用][C] Fenebrutinib compared to placebo and adalimumab in patients with inadequate response to either methotrexate therapy or prior TNF therapy: Phase 2 study
S Cohen, K Tuckwell… - ANNALS OF …, 2019 - BMJ PUBLISHING GROUP BRITISH …
[PDF][PDF] Fenebrutinib compared to placebo and adalimumab in patients with inadequate response to either methotrexate therapy or prior TNF therapy: phase 2 study
C StanleyCohen, K Tuckwell, D Fedkov - 2019 - ir.librarynmu.com
Conclusion: Improvements in treatment strategies during the last 25 years have resulted in
lower disease activity, less mortality, more DFR and better physical functioning of RA-
patients. ACPA+ patients, traditionally the most severe subset, benefited most from these
improvements and have become more similar to ACPA-patients.
lower disease activity, less mortality, more DFR and better physical functioning of RA-
patients. ACPA+ patients, traditionally the most severe subset, benefited most from these
improvements and have become more similar to ACPA-patients.
以上显示的是最相近的搜索结果。 查看全部搜索结果